Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Journal of Pharmacology and PharmacotherapeuticsNOW IN
    Article

    Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases

    Pasquale Ventrice1,2, Christian Leporini1,2, Jose’ Francisco Aloe3, Ettore Greco4, Giacomo Leuzzi1,2, Giuseppina Marrazzo1,2, Giovanni Battista Scorcia5, Donatella Bruzzichesi5, Varano Nicola5, Vincenzo Scorcia5★★ Corresponding author

    1. 1Department of Science of Health, School of Medicine, University of Catanzaro, Catanzaro, Italy.
    2. 2Department of Science of Health, Pharmacovigilance’s Centre Calabria Region, University Hospital Mater Domini, Catanzaro, Italy.
    3. 3Pharmacy Unit, Giovanni Paolo II Hospital, Lamezia Terme, Italy.
    4. 4Oncology Unit, Giovanni Paolo II Hospital, Lamezia Terme, Italy.
    5. 5Department of Ophthalmology, University of “Magna Graecia”, Catanzaro, Italy.

    CORRESPONDENCE

    Vincenzo Scorcia

    Department of Ophthalmology, University of “Magna Graecia”, Catanzaro, Italy.

    vscorcia@unicz.it

    Volume 4, Issue 4S · pp. S38–S39 · PUBLISHED 2013 · DOI: 10.4103/0976-500X.120947

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    Macular degeneration is the leading cause of blindness in developed countries. In the treatment of neovascular age-related macular degeneration, vascular endothelial growth factor (VEGF) has emerged as a key target for therapy. The intravitreal injection of anti-VEGF drugs has been widely employed to reduce the disease progression and improve the visual outcomes of the affected patients. However, each intravitreal inoculation poses a risk of several complications as infection, inflammation, endophthalmitis, intraocular inflammation, increase of intraocular pressure and vitreous hemorrhage. This short review evaluates the efficacy and the incidence of adverse drug reactions related to intravitreal administration of the main anti-VEGF drugs actually available: Bevacizumab, ranibizumab and aflibercept.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Ventrice, P., Leporini, C., Aloe, J. F., Greco, E., Leuzzi, G., Marrazzo, G., Scorcia, G. B., Bruzzichesi, D., Nicola, V., & Scorcia, V. (2013). Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases. Journal of Pharmacology and Pharmacotherapeutics, 4(4S), S38–S39. https://doi.org/10.4103/0976-500X.120947